CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• The Case For Non-Viral Circular Single-Stranded HDR Donors

  Enable efficient, low-toxicity genome editing without viral vectors. This cell-free circular ssDNA platform preserves stem cell fitness while supporting scalable manufacturing.

• Automation And Digital Solutions Can Help You Reach Your mRNA Manufacturing And Sustainability Goals

  Explore how digital solutions help streamline mRNA manufacturing by reducing costs, improving efficiency, and supporting sustainability by creating paperless processes for emerging therapeutics.

• Evaluating The Expression Patterns Of Multiple Inhibitory Receptors

  Discover how an innovative approach to interpreting T-cell exhaustion and inhibitory receptor expression is paving the way for innovative therapeutic approaches aimed at rejuvenating T-cell function.

• Scale-Up Of AAV Production In Fixed-Bed Bioreactors

  Consistent AAV production is critical for manufacturing. See how aligned strategies deliver comparable cell growth, metabolic trends, and rAAV5 titers from development through production.

• The Value Of Human Panel Testing Downstream Of Donor Screening In The Allogeneic Therapy Pipeline

  Allogeneic cell-based therapies require rigorous donor screening for adventitious viruses. qPCR-based assays enhance detection accuracy, sensitivity, and specificity, supplementing serological testing to ensure safer drug development and production.

• What Pharmacies Often Miss In USP <800> Compliance

  Master USP <800> compliance by transitioning from standalone equipment to an integrated system design. Review key protocols for a multi-layered strategy to mitigate cumulative drug risks.

• Automated Library Prep For A Nanopore DNA Barcoding Protocol

  A streamlined workflow reduces reagent use and hands‑on time while preserving long‑read sequencing quality. See how multiplexed offer an efficient option for scaling or mobilizing sequencing efforts.

• Speeding Up Safety: An Evaluation Of Mycoplasma Technology

  Rapid mycoplasma testing enhances cell and gene therapy safety by reducing turnaround time, minimizing sample needs, and delivering sensitive, reliable contamination detection across diverse matrices.

• Manufacturing Strategies To Industrialize Autologous Therapies

  Discover how a systematic approach to autologous cell therapy manufacturing can reduce costs, improve reliability, and accelerate access to life-changing treatments.

• Accelerated LVV Manufacturing Enabled By Platform Excellence

  Discover how a manufacturing platform enabled the rapid production of lentiviral vector in eight months. Learn the strategy used to balance speed, risk mitigation, and the highest quality standards.